breast cancer; immune subtypes; mutational burden; prognosis; survival
Mounting evidence supports a role for the immune system in breast cancer outcomes. The ability to distinguish highly immunogenic tumors susceptible to anti-tumor immunity from weakly immunogenic or inherently immune-resistant tumors would guide development of therapeutic strategies in breast cancer. Genomic, transcriptomic and clinical data from The Cancer Genome Atlas (TCGA) and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) breast cancer cohorts were used to examine statistical associations between tumor mutational burden (TMB) and the survival of patients whose tumors were assigned to previously-described prognostic immune subclasses reflecting favorable, weak or poor immune-infiltrate dispositions (FID, WID or PID, respectively). Tumor immune subclasses were associated with survival in patients with high TMB (TMB-Hi,
Women & Children
Earle A. Chiles Research Institute
Thomas, Alexandra; Routh, Eric D; Pullikuth, Ashok; Jin, Guangxu; Su, Jing; Chou, Jeff W; Hoadley, Katherine A; Print, Cristin; Knowlton, Nick; Black, Michael A; Demaria, Sandra; Wang, Ena; Bedognetti, Davide; Jones, Wendell D; Mehta, Gaurav A; Gatza, Michael L; Perou, Charles M; Page, David B; Triozzi, Pierre; and Miller, Lance D, "Tumor mutational burden is a determinant of immune-mediated survival in breast cancer." (2018). Articles, Abstracts, and Reports. 933.